Center For Research on Substance Use and Addiction

Offering pilot awards for competitive studies in the area of substance use and addiction.

The Center for Research on Substance Use and Addiction offers translational research pilot awards for competitive studies in the area of substance use and addiction.

Center Goals

To promote state-of-the-art research, education and dissemination of evidence-based practices focusing on:

Preclinical models that will support the development of personalized treatments for substance-related disorders
Population research involving epidemiology, community and policy interventions to promote population health
Clinical-translational research that will generate new knowledge and contribute to our learning healthcare system

Call for Pilot Proposals

Wake Forest Translational Alcohol Research Center

The Wake Forest Translational Alcohol Research Center (WF-TARC) invites applications for pilot grants to support research on behavioral correlates and neural substrates associated with vulnerability and resilience to alcohol use disorder. The goals of this program are to attract new scientific expertise to complement ongoing research supported by the WF-TARC, to encourage and promote multidisciplinary and translational alcohol research, and to support preliminary investigations to attract new extramural alcohol-related funding at Wake Forest School of Medicine. These awards are open to all faculty with a rank of Instructor or higher from Wake Forest Health Sciences. Current WF-TARC projects leverage the strengths and advantages of animal models and human subjects research and include molecular, cellular, circuit, and whole-brain analyses. Four pilot grants will be awarded for up to $22,500/year for two years (pending satisfactory progress). In addition, we are partnering with our Institutional Center for Research on Substance Use and Addiction (CRSUA) to solicit highly translational applications that include population health, clinical, and preclinical investigators. These joint WF-TARC/CRSUA awards, which will undergo both WF-TARC and CRSUA review, may have a budget of up to $55,000 in the first year (and $22,500 in the second year).

Submission Deadline: October 31, 2019
Start Date: January 1, 2020

If interested, please contact:
Sara R. Jones, PhD
srjones@wakehealth.edu

Associate Dean for Basic Science Research
Professor, Physiology and Pharmacology
Co-Director, WF-TARC
Principal Investigator, Pilot Project Core, WF-TARC

COVID Related Highlighted Reading List

An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19

When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis

Collision of the COVID-19 and Addiction Epidemics

Alcohol Policy and Coronavirus: An Open Research Agenda

COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications

Important Links

National Institute on Drug Abuse (NIDA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Office of National Drug Control Policy (ONDCP)

Substance Abuse and Mental Health Service Administration (SAMSHA)

National Institute of Mental Health (NIMH)

Leadership and Members

Leadership and center members are active in establishing multi-departmental and collaborative research programs. Members help attract and train new investigators, connect with regional communities, implement policy, and leverage resources across the School of Medicine.

Michael A. Nader, PhD

Director, Center for Substance Use and Addiction
Professor, Physiology and Pharmacology

Linda J. Porrino, PhD

Professor, Physiology and Pharmacology

Jeffrey L. Weiner, PhD

Professor, Physiology and Pharmacology

Laura J. Veach, PhD, LCAS, LCMHC

Professor, Trauma Surgery

Heather E. Douglas, MD

Assistant Professor, Psychiatry and Behavioral Medicine

Beth A. Reboussin, PhD

Professor, Biostatistics and Data Science

Kimberly G. Wagoner, DrPH, MPH

Assistant Professor, Social Sciences and Health Policy

See all Center Leadership and Members

Our Research

The most competitive proposals will involve a meaningful collaboration between a basic science and a clinical investigator, a clinical investigator and a population science investigator, or a basic science and a population science investigator. Funded applications will provide a rationale for particular relevance to the Wake Forest Baptist health care system and/or the communities and populations it serves.

Pilot Projects

2020

Colleen Hanlon, PhD (PI, Cancer Biology), Laura Veach and Elizabeth Shilling (Co-Is): The effect of dorsolateral prefrontal cortex theta burst stimulation on alcohol cue reactivity and cognitive control: a double-blind, sham controlled study of heavy alcohol drinkers with a history of alcohol related injury. [This is a shared award with Wake Forest Translational Alcohol Research Center]

Laura Cox, PhD (PI, Internal Medicine), Michael Olivier, James Daunais, Tim Howard, Sobha Puppala (Co-Is): Identification of hepatic and plasma molecular networks associated with drinking behavior in NHP.

Chris Gillette, PhD (PI, PA Studies): PIEPN: Provider intention for educating patients about naloxone. [Co-funded with the CTSI]

Heather Douglas, MD (Co-PI, Psychiatry) and Gagan Deep, PhD (Co-PI, Cancer Biology): Opioids effect on brain exosomes.

2019

Kiran Solingapuram Sai, PhD (PI, Radiology), Paul Czoty and Chris Whitlow (Co-Is): Evaluating microtubule binding as a potential imaging biomarker for alcohol addiction.

Robert W. Gould, PhD (PI, Physiology and Pharmacology), Robert Hurley (Co-I): Determining effects of prescription opioids on sleep and arousal in animal models of opioid use disorder (OUD) to inform novel treatment development.

2018

Mary Pylipow, MD -Prenatal Opioid Exposure: Effects on Infant Brain Development
Gagan Deep, PhD (HEAL Initiative) -Development of CSF-derived exosome signature in adult rhesus monkey exposed to cocaine throughout gestation
Erin Barnes, MD and Ernesto Aranda, MD (HEAL Initiative) -Randomized Pilot Study of Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films

2017

Leah Solberg Woods, PhD (PI, Internal Medicine), Jeff Weiner, Laura Veach (Co-Is): Using HS rats to understand the genetics of adolescent social isolation vulnerability to anxiety and alcohol use disorders

Hariom Yadav, PhD (PI, Internal Medicine), Akiva Mintz, Kiran Solingapuram Sai (Co-Is): Role of gut microbiome modulators on food-addiction of obesity in mice

Candice McNeil, MD (PI, Internal Medicine/Infectious Diseases), Kathleen Egan (Co-I): Bridging the Gap Between Provider Knowledge and Practices Focused on Minimizing Adverse Consequences Associated with the Use of Prescription Opioid

November 2020 Funding Announcements

The Tobacco Regulatory Science Program (TRSP)

The Tobacco Regulatory Science Program (TRSP) is an interagency partnership between the NIH and the FDA Center for Tobacco Products [fda.gov] to foster tobacco regulatory research. With the passage of the 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), the FDA acquired the authority to regulate the manufacture, marketing, and distribution of tobacco products in order to protect public health. Within the framework of the Tobacco Control Act, the NIH and FDA formed this partnership to establish a comprehensive research agenda in tobacco regulatory science.

TRSP offers several research funding opportunities focused on tobacco regulatory science. Investigator-initiated applications may also be submitted for NIH review. As you review the grant opportunities:

Review the current TRSP Research Priorities [prevention.nih.gov] page for topics relevant to the FDA Center for Tobacco Products.
Work with the NIH Program Officials listed in Section VII: NIH Agency Contacts of the Funding Opportunity Announcement (FOA) or Contact the NIH TRSP Mailbox.
Learn about the application review process. Note that the TRSP review criteria[prevention.nih.gov] are different from the standard NIH review criteria.

Find a list of current TRSP funding opportunities copied below:

Tobacco Regulatory Science Program (TRSP) Funding Opportunities and Announcements

The Tobacco Regulatory Science (R01 Clinical Trial Optional) - RFA-OD-19-028[grants.nih.gov] has been reissued with new research priorities. The next application date is February 13, 2021. LOI due 60 days prior to the application due date
Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 - Clinical Trial Not Allowed) - RFA-OD-19-022[grants.nih.gov]. The next application date is March 8, 2021. LOI due 60 days prior to the application due date.
Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research (R21 - Clinical Trial Not Allowed) - RFA-OD-19-021[grants.nih.gov]. The next application date March 8, 2021. LOI due 60 days prior to the application due date.
The K01 and K99/R00 RFAs were re-issued. The next application due date is February 8, 2021. LOI due 60 days prior to the application due date.
Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01)

o RFA-OD-20-008 [grants.nih.gov]non-clinical trial

o RFA-OD-20-011 [grants.nih.gov]clinical trial

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00)

o RFA-OD-20-009 [grants.nih.gov]non-clinical trial

o RFA-OD-20-010 [grants.nih.gov]clinical trial

NOSI: Research to Advance the Understanding of Tobacco Product Pharmacokinetic Research - NOT-OD-20-081 [grants.nih.gov]. This notice applies to due dates after July 17, 2020 and subsequent receipt dates through February 13, 2021.
For additional information on TRSP funding opportunities, visit the TRSP website [secure-web.cisco.com]

Notices from NIDA HIV/AIDS Program

* Notice of Participation of the National Institute on Drug Abuse(NIDA) in PA-19-042, "Engaging Men in HIV Testing, Prevention, and Care (R01 Clinical Trial Optional)"[grants.nih.gov]
(NOT-DA-20-095)
National Institute on Drug Abuse

* Notice of Participation of the National Institute on Drug Abuse(NIDA) in PA-19-050, "Engaging Men in HIV Testing, Prevention, and Care (R21 Clinical Trial Optional)"[grants.nih.gov]
(NOT-DA-20-096)
National Institute on Drug Abuse

* Notice of Participation of the National Institute on Drug Abuse(NIDA) in RFA-MD-21-001, "Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)" [grants.nih.gov]
(NOT-DA-21-009)
National Institute on Drug Abuse

* Notice of Participation of the National Institute on Drug Abuse(NIDA) in RFA-MD-21-002, "Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required)" [grants.nih.gov]
(NOT-DA-21-010)
National Institute on Drug Abuse

Also of Relevance:

Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic

Notice Number:

NOT-OD-20-123

NIH has just announced that because of the Covid-19 pandemic and the negative effects this has had on our ability to collect pilot data, they will permit a one-page summary of pilot findings to be submitted 30-days prior to when study section will review your application. That’s great news, especially if you were considering having to delay a Fall submission because you couldn’t collect enough pilot data!

https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-123.html [grants.nih.gov]

Education and Training

Graduate Programs

More Resources

More Resources

Institutes and Centers

Shared Resources and Cores

Public Health Sciences

Research and Faculty Labs

Clinical Trials

Symposia Series

Center For Research on Substance Use and Addiction

Center Goals

Call for Pilot Proposals

COVID Related Highlighted Reading List

Important Links

Leadership and Members

Michael A. Nader, PhD

Linda J. Porrino, PhD

Jeffrey L. Weiner, PhD

Laura J. Veach, PhD, LCAS, LCMHC

Heather E. Douglas, MD

Beth A. Reboussin, PhD

Kimberly G. Wagoner, DrPH, MPH